SOLVD Health, a patient intelligence company focused on precision solutions to improve health outcomes, has launched a comprehensive post-approval study for AvertD®, the first FDA-approved genetic test to assess the risk of opioid use disorder (OUD). The study will build on the results of earlier pivotal research and further demonstrate how AvertD® can support personalized, data-driven decision-making in real-world healthcare settings.
SOLVD Health has launched a prospective study to enroll up to 4,000 patients, using agile methods to collect comprehensive, real-world data from diverse demographic groups across the United States. The study is designed to confirm the predictive accuracy of AvertD® across different populations and to provide healthcare providers with vital, personalized insights to improve evidence-based pain management.
“This post-approval study for AvertD is not just about meeting regulatory requirements—it’s about tackling one of the most urgent public health issues we face today,” said Dr. Keri Donaldson, Founder and CEO of SOLVD Health. “Every day, healthcare providers and patients must navigate complex decisions around pain management. Our aim is to equip them with precise, personalized data to help guide those decisions and ultimately improve patient outcomes.”
The study will follow participants for up to five years, gathering long-term data on the effectiveness of genetic testing in assessing opioid use disorder (OUD) risk. The extended duration will also allow researchers to explore how genetic factors interact with environmental and behavioral influences, potentially uncovering new approaches for addiction prevention and intervention.
About SOLVD Health
SOLVD Health is a privately held company dedicated to disease prevention by making contextual health information accessible to all. Through innovative health tools, SOLVD Health empowers individuals and their healthcare providers to make informed decisions about their health and well-being. The company transforms complex biological data into actionable insights that drive better health outcomes.
